Tizanidine Tablet
Product Images NDC 60760-694

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 60760-694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tiz (Tizanidine 60760 694 15)

Label for Tizanidine tablets USP 2 mg by St. Mary's Medical Park Pharmacy. The label indicates a quantity of 15 tablets. Manufactured by Dr. Reddy's Laboratories Limited in India. Includes NDC 60760-694-15 and various placeholder details for lot and expiration dates. Storage instructions advise controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Fig1 (Fig1)

A pharmacokinetic line graph depicting plasma tizanidine concentration (ng/mL) over 26 hours post-dosing. It compares four conditions: 2 x 4 mg tizanidine tablets and capsules, each with and without food. The graph shows concentration peaks and declines for these different dosing scenarios.*

FDA Label Image

Fig2 (Fig2)

A line graph depicting improvement in Ashworth score over hours post-dose, comparing three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The x-axis indicates hours post-dose (0 to 6 hours) and the y-axis shows improvement in Ashworth score, with error bars for variability. The graph shows peak improvement around 2 hours post-dose for the 16 mg and 8 mg tizanidine groups.*

FDA Label Image

Fig3 (Fig3)

A line chart comparing improvement in Ashworth Score between tizanidine and placebo groups at three time points: end of titration (week 3), end of maintenance (week 7), and endpoint with last observation carried forward. The tizanidine group (mean dose 28.8 mg) shows greater improvement compared to placebo, with error bars indicating variability.*

FDA Label Image

Structure (Structure)

Chemical structure of the active ingredient Tizanidine hydrochloride, as depicted in the diagram. The structure shows the molecular arrangement relevant to this oral tablet formulation by St. Mary's Medical Park Pharmacy.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.